Background and objective: The receptor for advanced glycation end product (RAGE) is a multiligand cellsurface receptor abundantly expressed in the lung. RAGE/ligand interaction has been postulated to participate in the pathogenesis of inflammatory diseases, while soluble RAGE (sRAGE) might act as a decoy receptor. A functional polymorphism rs2070600 in the gene coding RAGE (AGER) might modulate its receptor function. The aim of this study was to investigate the association of AGER polymorphisms and circulatory sRAGE with the development and progression of idiopathic pulmonary fibrosis (IPF). Methods: This study comprised 87 Japanese patients with IPF and 303 healthy controls. Seven tag polymorphisms in AGER were genotyped and their distributions were compared. We also measured serum sRAGE levels, and evaluated the correlations of sRAGE levels with AGER polymorphisms and the prognosis of the patients with IPF. Results: The frequency of AGER rs2070600 genotype with minor allele was significantly higher in patients with IPF (OR = 1.84, 95% CI = 1.08-3.10). Additionally, the carriage of the rs2070600 minor allele and the presence of IPF were independently associated with reduced serum levels of sRAGE. Moreover, reduced sRAGE (≤471.8 pg/mL) was related to acute exacerbation of IPF and was an independent predictor of 5-year survival in patients with the disease (hazard ratio (HR) = 7.956, 95% CI = 1.575-53.34). Conclusion: These results suggest a possible association between a functional polymorphism in AGER and IPF
INTRODUCTION
The receptor for advanced glycation end product (RAGE) is a transmembrane receptor that binds numerous ligands in addition to advanced glycation end product, such as high-mobility group box 1 (HMGB1), S100 and amyloid β-peptide. RAGE/ligand interaction initiates pro-inflammatory intracellular signalling pathways 
SUMMARY AT A GLANCE
AGER rs2070600 polymorphism is frequent in patients with idiopathic pulmonary fibrosis (IPF). Reduced soluble receptor for advanced glycation end product (sRAGE) might be associated with poor prognosis of IPF. Our study suggests that RAGE and its polymorphism may be related to IPF and sRAGE is a potential prognostic marker for IPF. resulting in cellular activation and gene transcription. [1] [2] [3] The activation has been implicated in pathological inflammatory conditions, for example atherosclerosis, amyloidosis and acute lung injury/sepsis. [4] [5] [6] Although the expression of RAGE is at low levels in the majority of normal tissues, it is abundantly expressed in the normal lung, primarily in type 1 pneumocytes. 7, 8 Large-scale genome-wide association studies (GWASs) have demonstrated a significant relationship between a reduction in the ratio of forced expiratory volume per second to forced vital capacity (FEV 1 /FVC) and the functional polymorphism rs2070600 in the gene coding for RAGE (AGER). 9, 10 These observations indicate that RAGE might have physiological roles in the lung, and that polymorphisms in AGER can be associated with lung pathology. Furthermore, AGER polymorphisms are also associated with altered circulatory levels of soluble RAGE (sRAGE), 11, 12 which lacks the cytoplasmic domain of membrane-bound RAGE. Remarkably, the intact binding domains of sRAGE allow it to act as a decoy receptor for RAGE ligand, which may result in antiinflammatory responses. 13, 14 Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis, characterized by recurrent alveolar epithelial injury followed by aberrant tissue repair and excessive matrix deposition. 15 We have previously shown that the expression of both membranebound RAGE and soluble isoforms of RAGE are reduced in the lung tissue of IPF patients. 16 Additionally, Englert et al. showed that RAGE knockout mice develop pulmonary fibrosis with age and more severe fibrosis when exposed to asbestos. 17 However, other studies have shown that RAGE knockout is protective against bleomycin-induced pulmonary fibrosis. 18, 19 Although controversial, these results imply that dysregulation of RAGE in the lung is associated with the development of pulmonary fibrosis.
We recruited participants with IPF and healthy controls to explore the association of AGER polymorphisms and circulatory sRAGE with the development and progression of IPF. Our hypothesis was that patients with IPF have a greater expression polymorphisms in AGER and a reduction of circulatory levels of sRAGE compared with healthy controls.
METHODS

Subjects
A total of 87 Japanese patients with IPF and 303 healthy Japanese control subjects were included. Seventy-two IPF patients were diagnosed with usual interstitial pneumonia (UIP) patterns on HRCT and 15 IPF patients were diagnosed with possible UIP patterns on HRCT and histological UIP patterns by surgical lung biopsy, based on the American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria. 20 This study was approved by the Ethics Committee of Hiroshima University Hospital (IRB33 and M326) and all participants provided written informed consent.
DNA preparation and genotyping
Peripheral whole venous blood samples were obtained and stored at −80 C. Genomic DNA extraction was performed using the phenol-chloroform extraction and ethanol precipitation methods, as previously described. 21, 22 RAGE tag polymorphisms were selected from the HAPMAP database (minor allele frequency > 1%, HAP-MAP phase 2 + 3, August 2010, population of Japanese in Tokyo, Japan) and the tagger option in Haploview (r 2 > 0.8). 23, 24 Seven tag polymorphisms (rs3131300 A/G, rs2070600 C/T, rs2269422 T/C, rs1035798 G/A, rs184003 C/A, rs2853807 G/A and rs2071288 C/T) were genotyped in all participants (Table S1 , Supplementary Information). Genotypes were determined by using a commercially available PCR assay. The PCR mixture contained TaqMan Single Nucleotide Polymorphism (SNP) Genotyping Assay (C_11409142_10, C_15867521_20, C_2730-1459_10, C_8848032_1_, C_2412456_10, C_25630839_10 and C_15861169_10; Life Technologies Corp., Carlsbad, CA, USA), genomic DNA (2.0 g/mL) and TaqMan Fast Universal PCR Master Mix (Life Technologies Corp.). Real-time PCR analysis was conducted with an Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies Corp.).
Serum measurements
Serum samples were collected at diagnosis and stored at −80 C. Serum sRAGE levels were measured by commercially available ELISA kits according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). The mean minimum detectable dose of the ELISA kit is 78 pg/mL.
Statistical analysis
Genotype frequencies and allele frequencies were calculated by direct counting. The associations of genotype distributions and allele frequencies with the risk of IPF were assessed using the Pearson's chi-square test and OR, and no correction for multiple testing was performed because of the exploratory design and modest statistical power of this study.
Serum sRAGE levels were expressed as mean AE SD. The results were compared with a Mann-Whitney U-test and Pearson's chi-square test. Linear regression analysis was conducted to study the independent effects of baseline characteristics on serum sRAGE levels. The t-test and beta coefficients were used to determine the significance of the predictor and the direction of the relationship. Receiver operating characteristic (ROC) curve analysis was performed to find the optimal value of serum sRAGE for predicting 5-year survival in patients with IPF. Survival and onset of acute exacerbation were evaluated using the KaplanMeier approach and the log-rank test. Cox proportional hazards analysis was used to identify significant predictors of 5-year survival. If the correlation was statistically significant, the multivariate Cox proportional hazards model was adopted to determine whether the variables independently affected 5-year mortality in patients with IPF. All data analyses were performed using JMP statistical software version 11.2.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Subject characteristics
The characteristics of the total study population are shown in Table 1 . Patients with IPF were significantly older, had higher pack-year smoking histories and lower vital capacity (VC) (% predicted) compared with healthy controls. The genotype frequencies of the examined polymorphisms in AGER did not deviate from the Hardy-Weinberg equilibrium in patients with IPF and healthy controls (P > 0.19). The median observation period was 35.0 months in the patients with IPF.
AGER polymorphisms and IPF risk
Patients with the rs2070600 genotype with minor allele (T) had an increased risk of IPF relative to healthy controls in the dominant effect model (OR = 1.84, 95% CI = 1.08-3.10, P = 0.021) ( Table 2 ). There was also a non-significant tendency towards a higher frequency of rs2070600 minor allele (T) in patients with IPF (OR = 1.55, 95% CI = 0.98-2.41, P = 0.057) (Table S2 , Supplementary Information).
Baseline serum concentrations of sRAGE
For the blood analysis, 12 IPF patients were excluded because of the lack of serum samples and/or diagnosis of acute exacerbation of IPF at their first visit. One hundred and twenty healthy controls were randomly selected for the serum analysis. The baseline characteristics of this cohort, 75 patients with IPF and 120 healthy controls, were representative of the whole cohort (Table S3 , Supplementary Information). Serum sRAGE levels in patients with IPF were significantly lower than those in controls (608.5 AE 388.2 and 869.5 AE 340.5 pg/mL, P < 0.001) (Fig. 1A) . Serum sRAGE levels were also significantly lower in those subjects with the rs2070600 minor allele (T) compared with those without the allele (593.3 AE 286.9 and 855.0 AE 391.8 pg/mL, P < 0.001). The other six polymorphisms were not associated with altered levels of sRAGE (Table S4 , Supplementary Information). In the subset analysis, serum sRAGE levels were significantly lower in subjects with the rs2070600 minor allele (T) than those without for both IPF patients and healthy controls (482.9 AE 256.5 and 687.7 AE 436.2 pg/ mL, P = 0.037; 684.8 AE 281.6 and 945.6 AE 334.7 pg/ mL, P < 0.001, respectively) (Fig. 1B,C) . Multivariate linear regression analysis revealed that the presence of IPF and the rs2070600 minor allele (T) were independently associated with reduced sRAGE levels (t = −2.69, β = −0.28, P = 0.008; t = −4.30, β = −0.29, P < 0.001, respectively) (Table 3) . Additionally, there is no significant correlation between baseline pulmonary functions and serum levels of sRAGE in the patients with IPF (Table S5 , Supplementary Information).
Prognostic value of serum sRAGE
The optimal cut-off level of serum sRAGE for predicting 5-year survival rates was 471.8 pg/mL, which was determined by the ROC curve with area under the curve (AUC) value of 0.711 (95% CI = 0.552-0.870) (Fig. S1, Supplementary Information) . The 5-year survival rates were compared in IPF patients with serum sRAGE levels above or below 471.8 pg/mL, using the Kaplan-Meier method and log-rank test ( Fig. 2A) .
Survival rates were significantly lower in patients with lower levels of sRAGE (P = 0.012). During the 5-year observation period, 20 patients were diagnosed with acute exacerbation of IPF. 25 The patients with lower serum sRAGE levels (≤471.8 pg/mL) also had a shorter follow-up period before the onset of acute exacerbation (P = 0.001) (Fig. 2B) . However, there was no significant difference in 5-year survival between IPF patients with or without the rs2070600 minor allele (T), as determined by Kaplan-Meier analysis (P = 0.455) (Fig. S2 , Supplementary Information). In the univariate Cox proportional hazards analysis, sRAGE (≤471.8 pg/mL), VC (% predicted) and diffusing capacity of the lung for carbon monoxide (DL CO ) (% predicted) were significantly correlated with survival. The multivariate analysis revealed that sRAGE (≤471.8 pg/mL) was the independent predictor of 5-year survival adjusted for age, sex, BMI, packyears and VC (% predicted) (hazard ratio (HR) = 7.956, 95% CI = 1.575-53.34, P = 0.011) ( Table 4) .
DISCUSSION
In the present study, we showed that the AGER rs2070600 genotype with minor allele (T) was significantly more frequent in patients with IPF compared with healthy controls. Additionally, the presence of rs2070600 minor allele (T) and IPF were independently correlated with reduced levels of serum sRAGE. Decreased sRAGE was associated with poorer prognosis in patients with IPF. These data suggest that rs2070600 in AGER may be associated with the development of IPF and circulatory sRAGE might have prognostic value in patients with the disease. In the multivariate analysis, VC (% predicted) was excluded because of the correlation with the presence of IPF.
† Serum analysis included 75 IPF patients 120 control subjects. ‡ P < 0.05 (linear regression analysis). IPF, idiopathic pulmonary fibrosis; sRAGE, soluble receptor for advanced glycation end product; VC, vital capacity.
The rs2070600 polymorphism is a glycine to serine switch at position 82, on exon 3 of AGER, a region that codes for the ligand-binding site. 26 Hofmann et al. showed that the rs2070600 T allele variant displayed increased ligand-binding affinity of RAGE, and enhanced activation of post-RAGE pro-inflammatory signalling pathways. 27 Additionally, He et al. showed that RAGE knockout in mice is protective against bleomycin-induced lung fibrosis and is associated with reduced concentration of RAGE ligands in bronchoalveolar lavage fluid (BALF). 18 This suggested that RAGE/ ligand interaction might play a pivotal role in the development of lung fibrosis. From these observations, we speculate that the rs2070600 minor allele (T) may be associated with development of IPF by enhancing RAGE/ligand affinity and post-RAGE signalling.
The present study showed that the rs2070600 minor allele (T) was independently associated with reduced levels of serum sRAGE in patients with IPF and in control subjects. Previous literature has shown that serum sRAGE levels in subjects with the rs2070600 minor allele (T) are significantly decreased in the Caucasian population, independent of age, sex and glucose metabolism status. 11 This polymorphism was also associated with circulatory sRAGE levels in individuals affected by COPD in an international multicentre study. 12 These observations suggest that the rs2070600 minor allele (T) might be associated with lower levels of circulatory sRAGE, independent of disease status. The mechanism is unknown, but one possibility is that enhanced RAGE/ligand affinity in subjects with rs2070600 polymorphism may relate to reduced circulatory levels of sRAGE, because interaction between sRAGE and RAGE ligands promotes diminishing sRAGE in the circulation. 28 In addition, this study was the first to show that the presence of IPF was significantly associated with reduced serum sRAGE levels in the circulation independent of the presence of the rs2070600 minor allele (T). This result potentially reflects reduced expression of RAGE in IPF lung tissue. 16 In the present study, we have shown that reduced levels of circulatory sRAGE predict exacerbation and poor prognosis in patients with IPF independent of lung function. Previous reports have shown that sRAGE might have anti-inflammatory effects by acting as a decoy receptor for RAGE ligands. 1, 13, 14 RAGE ligands, especially HMGB1, are thought to be central mediators in acute lung injury, 29 and HMGB1 levels have been shown to increase in blood and BALF of acute exacerbated IPF patients. 30 Additionally, Zhang et al. demonstrated that exogenous sRAGE treatment has a protective effect in a 31 These findings suggest that aberrant sRAGE/ ligand balance might play a role in the pathogenesis of acute lung injury and exacerbation of IPF. Further investigation is necessary to clarify the mechanism of sRAGE in the progression and exacerbation of IPF and to determine the utility of circulatory sRAGE as a disease marker in patients with IPF.
This study has several limitations. First, there were some differences in the baseline characteristics, especially age and smoking history, between IPF patients and healthy subjects. The reference ranges for serum sRAGE levels in relation to age and smoking history are not clearly established; however, in the present study, serum levels of sRAGE were not independently correlated with these characteristics. Second, a replication study is necessary to re-evaluate the prognostic cut-off level of circulatory sRAGE to confirm its predictive value. Third, this study investigated a relatively small cohort of the Japanese population, and alpha adjustments were not performed because of the exploratory design. Therefore, the association of rs2070600 polymorphism with IPF susceptibility should be confirmed in a large cohort of various ethnicities. Recently, AGER rs2070600 minor allele (T) has been shown to be associated with higher FEV 1 /FVC in GWASs in a European population. 9, 10 Additionally, rs2070600 minor allele (T) was also shown to be protective against COPD in a Caucasian population. 32 These reported observations regarding FEV 1 /FVC and COPD appear to oppose our results, because in this present study, the same polymorphism was correlated with susceptibility to IPF. It should be noted that previous literature has shown that RAGE might have several homeostatic roles in the lung, 33 but that augmented RAGE/ligand pathway activation might be involved in lung pathology. 34 Therefore, it could be hypothesized that enhanced post-RAGE signalling, as influenced by the rs2070600 minor allele, can play a protective or deleterious role in a range of lung diseases.
In conclusion, the present results demonstrate an association between a functional polymorphism in AGER and IPF. This study has also shown that the same polymorphism and the presence of IPF were independently related to decreased levels of circulatory sRAGE, and that reduced sRAGE was related to poorer prognosis of IPF. These findings suggest that RAGE may be a key molecule in the development and progression of IPF, and sRAGE might be a potential prognostic marker for the disease.
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